Innoviva (INVA) Accounts Payables (2010 - 2026)
Innoviva posted quarterly Accounts Payables of $6.5 million for Q1 2026, up 38.68% year-on-year from $4.7 million in Q1 2025, and up 31.25% on a QoQ basis from $5.0 million in Q4 2025.
Innoviva (INVA) has 17 years of Accounts Payables data on file, last reported at $6.5 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 38.68% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $6.5 million (up 38.68% YoY), and the FY2025 full-year result was $5.0 million, up 132.93% from the prior year.
- Accounts Payables for Q1 2026 stood at $6.5 million, up from $5.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $6.7 million in Q4 2023 and bottomed at $890000.0 in Q1 2024.
- The 5-year median for Accounts Payables is $4.3 million (2022), against an average of $4.2 million.
- The widest annual swing landed in 2022, when Accounts Payables surged 14310.0%; it then slumped 85.0% in 2024.
- A 5-year view of Accounts Payables shows it stood at $2.9 million in 2022, then soared by 128.55% to $6.7 million in 2023, then plunged by 68.26% to $2.1 million in 2024, then jumped by 132.93% to $5.0 million in 2025, then jumped by 31.25% to $6.5 million in 2026.
- The last three Accounts Payables figures came in at $6.5 million (Q1 2026), $5.0 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 6.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.52 Mn |
| Dec 31, 2025 | 4.97 Mn |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | 5.38 Mn |
| Mar 31, 2025 | 4.70 Mn |
| Dec 31, 2024 | 2.13 Mn |
| Sep 30, 2024 | 4.17 Mn |
| Jun 30, 2024 | 2.04 Mn |
| Mar 31, 2024 | 890,000.00 |
| Dec 31, 2023 | 6.72 Mn |
| Sep 30, 2023 | 3.78 Mn |
| Jun 30, 2023 | 4.59 Mn |
| Mar 31, 2023 | 5.93 Mn |
| Dec 31, 2022 | 2.94 Mn |
| Sep 30, 2022 | 3.81 Mn |
| Jun 30, 2022 | 4.32 Mn |
| Mar 31, 2022 | 1.81 Mn |
| Dec 31, 2021 | 27,000.00 |
| Sep 30, 2021 | 89,000.00 |
| Jun 30, 2021 | 30,000.00 |
| Mar 31, 2021 | 14,000.00 |
| Dec 31, 2020 | 66,000.00 |
| Sep 30, 2020 | 623,000.00 |
| Jun 30, 2020 | 195,000.00 |
| Mar 31, 2020 | 122,000.00 |
| Dec 31, 2019 | 10,000.00 |
| Sep 30, 2019 | 35,000.00 |
| Jun 30, 2019 | 1.14 Mn |
| Mar 31, 2019 | 144,000.00 |
| Dec 31, 2018 | 11,000.00 |
| Sep 30, 2018 | 109,000.00 |
| Jun 30, 2018 | 58,000.00 |
| Mar 31, 2018 | 66,000.00 |
| Dec 31, 2017 | 601,000.00 |
| Sep 30, 2017 | 629,000.00 |
| Jun 30, 2017 | 277,000.00 |
| Mar 31, 2017 | 2.30 Mn |
| Dec 31, 2016 | 128,000.00 |
| Sep 30, 2016 | 528,000.00 |
| Jun 30, 2016 | 137,000.00 |
| Mar 31, 2016 | 576,000.00 |
| Dec 31, 2015 | 818,000.00 |
| Sep 30, 2015 | 154,000.00 |
| Jun 30, 2015 | 462,000.00 |
| Mar 31, 2015 | 1.03 Mn |
| Sep 30, 2014 | 573,000.00 |
| Jun 30, 2014 | 1.80 Mn |
| Mar 31, 2014 | 5.55 Mn |
| Dec 31, 2013 | 7.58 Mn |
| Sep 30, 2013 | 5.73 Mn |
| Jun 30, 2013 | 4.83 Mn |
| Mar 31, 2013 | 3.53 Mn |
| Dec 31, 2012 | 5.38 Mn |
| Sep 30, 2012 | 4.76 Mn |
| Jun 30, 2012 | 4.99 Mn |
| Mar 31, 2012 | 5.31 Mn |
| Dec 31, 2011 | 5.81 Mn |
| Sep 30, 2011 | 3.70 Mn |
| Jun 30, 2011 | 2.17 Mn |
| Dec 31, 2010 | 2.13 Mn |